Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.45 |
| ▸ | STK17B | O94768 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 4/20 | 0.45 |
| ▸ | MALT1 | Q9UDY8 | 4/20 | 0.44 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3450341 | 0.93 | MAPK1 (0.46) | MAPK1STK17ASTK17BAXLMALT1 | |
| SCHEMBL3452720 | 0.91 | MAPK1 (0.51) | MAPK1STK17ASTK17BAXLEGFR | |
| SCHEMBL3449764 | 0.91 | MAPK1 (0.51) | MAPK1STK17ASTK17BAXLEGFR | |
| SCHEMBL3344180 | 0.90 | NPC1 (0.53) | MAPK1EGFRCDK2NPC1RAB9A | |
| SCHEMBL3450023 | 0.90 | MAPK1 (0.50) | MAPK1STK17ASTK17BAXLEGFR | |
| SCHEMBL3449638 | 0.90 | MAPK1 (0.50) | MAPK1STK17ASTK17BAXLEGFR | |
| SCHEMBL3451168 | 0.90 | MAPK1 (0.44) | MAPK1STK17ASTK17BAXLMALT1 | |
| SCHEMBL3451371 | 0.89 | FGFR1 (0.45) | MAPK1EGFRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3448723 | 0.89 | LCK (0.48) | MAPK1STK17ASTK17BAXLMALT1 | |
| SCHEMBL13310378 | 0.88 | BRD4 (0.52) | MAPK1STK17ASTK17BAXLEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | MAPK1 2905/4885STK17A 1984/4885STK17B 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.